Off-label use of bevacizumab in patients diagnosed with age-related macular degeneration: a systematic review and meta-analysis

Bibliographic Details
Main Author: Estarreja, João
Publication Date: 2024
Other Authors: Mendes, Priscila, Silva, Carina, Camacho, Pedro, Mateus, Vanessa
Format: Article
Language: eng
Source: Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
Download full: http://hdl.handle.net/10400.21/17616
Summary: Background: Age-related macular degeneration (AMD) is the leading cause of vision loss in elderly people. Current pharmacological treatment in vascular AMD includes anti-VEGF agents, such as ranibizumab and aflibercept. Additionally, the off-label use of bevacizumab has been shown to be effective and has a lower cost, making it an interesting pharmacological approach; however, there is no consensus about its use. Therefore, this systematic review and meta-analysis aims to evaluate the efficacy, safety, and efficiency of bevacizumab in AMD patients. Methods: This review only focused on randomized controlled clinical trials published in 2010 in the MEDLINE database that compared the effect of bevacizumab with ranibizumab. The risk of bias in each included study was assessed using the CASP Randomised Clinical Trials checklist. Results: Twelve studies were included for qualitative synthesis, and nine of them were considered for meta-analysis. Bevacizumab-treated patients showed a significantly reduced neovascularization in a longer spectrum of time; however, they had a higher incidence of endophthalmitis than those treated with ranibizumab. Regarding efficiency, the mean number of administrations was reduced in the treatment with bevacizumab in comparison to ranibizumab. Conclusions: Clinical evidence demonstrates that bevacizumab has efficacy and safety profiles comparable with ranibizumab; however, it is relatively more efficient.
id RCAP_57f87f6d5aa6d9730992f3a7f89e8401
oai_identifier_str oai:repositorio.ipl.pt:10400.21/17616
network_acronym_str RCAP
network_name_str Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
repository_id_str https://opendoar.ac.uk/repository/7160
spelling Off-label use of bevacizumab in patients diagnosed with age-related macular degeneration: a systematic review and meta-analysisOphthalmologyAge-related macular degenerationAMDBevacizumabDrug therapynAMDNeovascular age-related macular degenerationWet macular degenerationFCT_UIDP/05608/2020FCT_UIDB/05608/2020Background: Age-related macular degeneration (AMD) is the leading cause of vision loss in elderly people. Current pharmacological treatment in vascular AMD includes anti-VEGF agents, such as ranibizumab and aflibercept. Additionally, the off-label use of bevacizumab has been shown to be effective and has a lower cost, making it an interesting pharmacological approach; however, there is no consensus about its use. Therefore, this systematic review and meta-analysis aims to evaluate the efficacy, safety, and efficiency of bevacizumab in AMD patients. Methods: This review only focused on randomized controlled clinical trials published in 2010 in the MEDLINE database that compared the effect of bevacizumab with ranibizumab. The risk of bias in each included study was assessed using the CASP Randomised Clinical Trials checklist. Results: Twelve studies were included for qualitative synthesis, and nine of them were considered for meta-analysis. Bevacizumab-treated patients showed a significantly reduced neovascularization in a longer spectrum of time; however, they had a higher incidence of endophthalmitis than those treated with ranibizumab. Regarding efficiency, the mean number of administrations was reduced in the treatment with bevacizumab in comparison to ranibizumab. Conclusions: Clinical evidence demonstrates that bevacizumab has efficacy and safety profiles comparable with ranibizumab; however, it is relatively more efficient.MDPIRCIPLEstarreja, JoãoMendes, PriscilaSilva, CarinaCamacho, PedroMateus, Vanessa2024-07-31T09:25:11Z2024-072024-07-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10400.21/17616eng10.3390/ph17081000info:eu-repo/semantics/openAccessreponame:Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)instname:FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologiainstacron:RCAAP2025-02-12T08:29:00Zoai:repositorio.ipl.pt:10400.21/17616Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireinfo@rcaap.ptopendoar:https://opendoar.ac.uk/repository/71602025-05-28T19:55:59.983470Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) - FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologiafalse
dc.title.none.fl_str_mv Off-label use of bevacizumab in patients diagnosed with age-related macular degeneration: a systematic review and meta-analysis
title Off-label use of bevacizumab in patients diagnosed with age-related macular degeneration: a systematic review and meta-analysis
spellingShingle Off-label use of bevacizumab in patients diagnosed with age-related macular degeneration: a systematic review and meta-analysis
Estarreja, João
Ophthalmology
Age-related macular degeneration
AMD
Bevacizumab
Drug therapy
nAMD
Neovascular age-related macular degeneration
Wet macular degeneration
FCT_UIDP/05608/2020
FCT_UIDB/05608/2020
title_short Off-label use of bevacizumab in patients diagnosed with age-related macular degeneration: a systematic review and meta-analysis
title_full Off-label use of bevacizumab in patients diagnosed with age-related macular degeneration: a systematic review and meta-analysis
title_fullStr Off-label use of bevacizumab in patients diagnosed with age-related macular degeneration: a systematic review and meta-analysis
title_full_unstemmed Off-label use of bevacizumab in patients diagnosed with age-related macular degeneration: a systematic review and meta-analysis
title_sort Off-label use of bevacizumab in patients diagnosed with age-related macular degeneration: a systematic review and meta-analysis
author Estarreja, João
author_facet Estarreja, João
Mendes, Priscila
Silva, Carina
Camacho, Pedro
Mateus, Vanessa
author_role author
author2 Mendes, Priscila
Silva, Carina
Camacho, Pedro
Mateus, Vanessa
author2_role author
author
author
author
dc.contributor.none.fl_str_mv RCIPL
dc.contributor.author.fl_str_mv Estarreja, João
Mendes, Priscila
Silva, Carina
Camacho, Pedro
Mateus, Vanessa
dc.subject.por.fl_str_mv Ophthalmology
Age-related macular degeneration
AMD
Bevacizumab
Drug therapy
nAMD
Neovascular age-related macular degeneration
Wet macular degeneration
FCT_UIDP/05608/2020
FCT_UIDB/05608/2020
topic Ophthalmology
Age-related macular degeneration
AMD
Bevacizumab
Drug therapy
nAMD
Neovascular age-related macular degeneration
Wet macular degeneration
FCT_UIDP/05608/2020
FCT_UIDB/05608/2020
description Background: Age-related macular degeneration (AMD) is the leading cause of vision loss in elderly people. Current pharmacological treatment in vascular AMD includes anti-VEGF agents, such as ranibizumab and aflibercept. Additionally, the off-label use of bevacizumab has been shown to be effective and has a lower cost, making it an interesting pharmacological approach; however, there is no consensus about its use. Therefore, this systematic review and meta-analysis aims to evaluate the efficacy, safety, and efficiency of bevacizumab in AMD patients. Methods: This review only focused on randomized controlled clinical trials published in 2010 in the MEDLINE database that compared the effect of bevacizumab with ranibizumab. The risk of bias in each included study was assessed using the CASP Randomised Clinical Trials checklist. Results: Twelve studies were included for qualitative synthesis, and nine of them were considered for meta-analysis. Bevacizumab-treated patients showed a significantly reduced neovascularization in a longer spectrum of time; however, they had a higher incidence of endophthalmitis than those treated with ranibizumab. Regarding efficiency, the mean number of administrations was reduced in the treatment with bevacizumab in comparison to ranibizumab. Conclusions: Clinical evidence demonstrates that bevacizumab has efficacy and safety profiles comparable with ranibizumab; however, it is relatively more efficient.
publishDate 2024
dc.date.none.fl_str_mv 2024-07-31T09:25:11Z
2024-07
2024-07-01T00:00:00Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10400.21/17616
url http://hdl.handle.net/10400.21/17616
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.3390/ph17081000
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv MDPI
publisher.none.fl_str_mv MDPI
dc.source.none.fl_str_mv reponame:Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
instname:FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia
instacron:RCAAP
instname_str FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia
instacron_str RCAAP
institution RCAAP
reponame_str Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
collection Repositórios Científicos de Acesso Aberto de Portugal (RCAAP)
repository.name.fl_str_mv Repositórios Científicos de Acesso Aberto de Portugal (RCAAP) - FCCN, serviços digitais da FCT – Fundação para a Ciência e a Tecnologia
repository.mail.fl_str_mv info@rcaap.pt
_version_ 1833598404269178880